Education
About Us
Working with TipRanks
Follow Us
Stevanato Group (STVN)
NYSE:STVN
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.1Last Year’s EPS
0.09Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: 9.55%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted growth in high-value solutions and the Biopharmaceutical and Diagnostic Solutions segment, along with significant improvements in free cash flow and progress in expansion projects. However, challenges remain in the Engineering segment and vial revenue, with a notable decline in gross profit margins. The company's efforts to address these challenges and invest in growth areas indicate a balanced outlook.Company Guidance
In the Stevanato Group's fourth quarter and year-end 2024 conference call, the company provided guidance for 2025 with several key metrics. They anticipate 2025 revenue between €1.160 billion and €1.190 billion, driven by mid to high single-digit growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, particularly in high-value syringes. Adjusted EBITDA is projected between €293 million and €306.3 million, with an adjusted diluted EPS range of €0.51 to €0.55. The company expects gross profit margins to improve by 100 to 140 basis points due to better performances in their Fishers and Latina facilities, as well as a higher mix of high-value solutions. Capital expenditures are forecasted at €310 million to €340 million before customer contributions, with net CapEx expected between €250 million and €280 million. Free cash flow is projected to improve, ranging from negative €40 million to negative €60 million. The company also foresees a gradual recovery in vial demand throughout 2025, with a more robust second half of the year.Growth in Biopharmaceutical and Diagnostic Solutions
The Biopharmaceutical and Diagnostic Solutions (BDS) segment grew by 6% in 2024, driven by robust demand for high-value syringes. Revenue from injectable biologics increased by 24% year-over-year and represented 34% of BDS revenue compared to 30% last year.
High-Value Solutions Revenue Increase
Revenue from high-value solutions grew by 9% to a record €131 million in Q4 2024, representing approximately 40% of total revenue. This was driven by growth in premium performance syringes and other product categories.
Progress in Expansion Projects
The company generated its first commercial revenue in Fishers, Indiana, and the Latina project in Italy turned profitable at a gross profit margin level in Q3 2024. These projects are expected to continue scaling and contribute to future growth.
Improved Free Cash Flow
Free cash flow improved significantly from a negative €333.9 million in 2023 to a negative €148.5 million in 2024, driven by increased cash flow from operations and lower capital expenditures.
---
STVN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
STVN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $19.06 | $20.70 | +8.60% |
| Nov 05, 2024 | $19.38 | $22.50 | +16.10% |
| Aug 06, 2024 | $18.79 | $19.87 | +5.75% |
| May 09, 2024 | $26.83 | $21.04 | -21.58% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Stevanato Group (STVN) report earnings?
Stevanato Group (STVN) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Stevanato Group (STVN) earnings time?
Stevanato Group (STVN) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STVN EPS forecast?
STVN EPS forecast for the fiscal quarter 2025 (Q1) is 0.1.
---